Keywords: astrazeneca, enrolls, vandetanib, ph, iii, trial, nsclc
AstraZeneca enrolls vandetanib Ph III trial in NSCLC
Article | 17 March 2008
Anglo-Swedish drug major AstraZeneca has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
